Please login to the form below
warfarin
This page shows the latest warfarin news and features for those working in and with pharma, biotech and healthcare.
FDA clears first generics of Pfizer/BMS’ anticoagulant Eliquis
Unlike older anticoagulants like warfarin, “direct oral anticoagulants…do not require repeated blood testing,” said Woodcock.
Latest news
-
Xarelto no better than aspirin in secondary stroke study
The overall NOAC market is growing strongly in the face of a string of new studies showing the new drugs' benefits over older anticoagulants such as warfarin, but Xarelto has seen
-
Xarelto beats aspirin for recurrent blood clots
Meanwhile, the overall NOAC market is growing strongly in the face of a string of new studies showing the new drugs' benefits over older anticoagulants such as warfarin.
-
Bayer defends Xarelto as pivotal trial scrutinised
The trial used a device called INRatio, manufactured by Alere, to determine whether doses of warfarin should be adjusted to keep the drug in the right therapeutic range. ... The implication is that patients on warfarin may have been more prone to bleeds
-
Daiichi Sankyo licenses clot-busting antibody
Meanwhile, anticoagulants such as warfarin and the newer novel oral anticoagulant (NOAC) class can prevent clots from forming but are unable to dissolve them when already present.
-
NICE recommends Daiichi Sankyo's Lixiana for DVT and PE
around £26, 000 per quality-adjusted life year (QALY), though it noted there are no definitive costs for warfarin monitoring. ... In terms of its clinical effectiveness Daiichi said Lixiana proven efficacy and a significantly better bleeding profile
More from news
Approximately 1 fully matching, plus 72 partially matching documents found.
Latest Intelligence
-
Immuno-oncology is fundamentally changing what value means, but how quickly can the pharma marketing, educational and service model change to reflect that?
Specialist clinics, required to safely manage the potentially tricky long-term use of warfarin, were well-established and represented a significant drain on NHS resources. ... NOACs were far safer for patients and did not have anywhere near the same
-
Bringing about digital health change
Roche believes it is on to a winner with its CoaguChek system, developed in collaboration with QL, to help warfarin patients self monitor so they don't have to travel to
-
Pharma–payer partnerships – rhetoric or reality?
The class is likely to replace the current standard of care (warfarin) which has been around for over 50 years. ... Despite being considered a 'dirty' drug warfarin has spawned the development of complex blood monitoring clinics and associated medical
-
Modern anticoagulants threaten status quo
Warfarin, an oral vitamin K antagonist (VKA) approved in the early 1950s, has ruled the anticoagulant market for nearly six decades. ... Interestingly, a study published in Stroke in March 2012 found that dabigatran etexilate was a cost-effective
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Account Supervisor – Leading Healthcare Advertising Agency – New...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Medical Writer – Creative Healthcare Advertising – New Yo...
-
Highly Competitive Salary, Bonus &Benefits
-
B2B media account director
-
Competitive salary
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- First trial of a vaccine against Alzheimer’s launches
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting
- bluebird bio’s beti-cel accepted for priority review by FDA
- AstraZeneca officially opens new R&D facility in UK
- As HCPs Increasingly Expect Personalized Engagement, Pharmas Turn to Modular Intelligent Content. How Does This Work?
- COVID-19 vaccines against Omicron may be fast-tracked
- BMS’ new JAK inhibitor enters regulatory pathways
- Onyx Health Announces Two Top Appointments
- Omicron prompts global action
- Novo Nordisk growth takes a hit with China deal
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- Six ways to improve diversity in clinical trials
- Innovation in a digital context is not about technology – it’s about people
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- Novartis forms coronavirus alliance with life sciences companies
- Pfizer lifts 2021 guidance as sales of its BioNTech-partnered vaccine continue to climb
PMHub
Nucleus Global
Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...
Latest intelligence
- Webinar:
- Securing a future for telehealth with immersive market research insights...
- Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
- How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
- Six ways to improve diversity in clinical trials
- Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...
